ABOUT BIOSOTOP
Opening new frontiers in metabolic diagnosis with stable-isotope drugs
Biosotop focuses on medical stable-isotope metabolic tracers, building a complete path from molecular probes and clinical registration to drug-device commercialization around MR metabolic imaging.
Company Overview
Starting from molecular tracer drugs to connect multi-nuclear MR equipment with precision-medicine applications
The company's core products play a clinical role similar to PET radiopharmaceuticals, but use stable-isotope labeling — non-radioactive and broadly safe — suitable for tumor metabolism assessment, efficacy monitoring and mechanism research.
Company Name
Shenzhen Biosotop Biotechnology Co., Ltd.
Founded
August 2019
Registered Address
A1303, Shenzhen National Engineering Laboratory Building, No. 20 Gaoxin South 7th Road, Nanshan District, Shenzhen
Main Products
Stable-isotope metabolic tracer drugs for MR imaging
Founded in Shenzhen, August 2019
Sustained investment in stable-isotope drug R&D
Spanning drug synthesis, imaging medicine and clinical translation
Advancing IND filing and commercial scale-up
Development Path
From research sales to IND registration, then to clinical and equipment-synergized scale-up
Started R&D of the deuterated glucose tracer and achieved kilogram-scale production.
Achieved research sales and advanced strategic cooperation with equipment vendors.
BST001 submitted its pre-IND application, entering a key registration phase.
Expected to obtain NMPA clinical trial approval, advancing clinical translation.